{"filings":[{"id":499676,"accession_number":"0001193125-26-228958","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2026-05-18T20:21:36+00:00","items":["5.02","9.01"],"status":"ready","headline":"Innoviva directors Small and DiPaolo resign; Josephine Linden elected to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Derek Small (CEO of Syndeio) and Mark DiPaolo resigned May 12 to focus on Syndeio growth.","Resignations not related to any disagreement with Innoviva's operations or policies.","Josephine Linden elected to board effective May 18; qualifies as independent director.","Linden receives initial RSU of $125K, prorated RSU of $206,250, and options for 9,166 shares.","Linden will serve on Audit Committee; board cites her 25+ years at Goldman Sachs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91145,"accession_number":"0001193125-26-209044","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).","Net product sales $41.4M (+37% YoY); US sales $34.2M led by GIAPREZA $19.7M, XACDURO $11.6M.","Net income $186.6M ($2.52 EPS) driven by $191.2M favorable fair value change in equity investments, primarily Armata Pharmaceuticals.","Repurchased 971,066 shares for $20.4M in Q1 under $125M share repurchase program.","NUZOLVENCE (zoliflodacin) FDA-approved Dec 2025; availability expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":97994000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91144,"accession_number":"0001193125-26-204243","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Innoviva shareholders reelect board, approve compensation and equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Small (56.8M for), DiPaolo (50.1M), Haimovitz (56.8M), Schlesinger (53.5M), Raifeld (58.9M).","Advisory say-on-pay approved: 56.2M for (95.2%), 2.8M against, 158k abstain.","Ratification of Deloitte & Touche as auditor for FY2026: 66.0M for (99.9%), 16.6k against.","2026 Equity Incentive Plan approved: 55.4M for (93.6%), 3.8M against, 36k abstain.","Broker non-votes of 6.8M shares on director elections and advisory compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101070,"accession_number":"0001193125-26-071974","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).","Royalty revenue from GSK $250.3M; IST U.S. net product sales $119.2M (+47% YoY).","FDA approved NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea in Dec 2025.","Guidance: IST U.S. net product sales at least $150M in 2026.","$125M repurchase program initiated; 797,298 shares repurchased for $16.0M as of year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":3.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":411328000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117414,"accession_number":"0001104659-25-107014","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q3: Revenue $107.8M (+20% YoY), Net Income $89.9M, $125M Buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $107.8M (+20% YoY); GSK royalty $63.4M; net product sales $47.3M (U.S. $29.9M, +52% YoY).","Net income $89.9M ($1.30 basic EPS) vs $1.2M ($0.02) in Q3 2024; driven by $62.3M fair-value gains on equity investments.","Income from operations $34.6M, down 20% primarily due to non-recurring R&D expense.","Board authorized $125M share repurchase program; $192.5M of convertible notes converted into 11.1M shares in August.","ZEVTERA U.S. launch in July; zoliflodacin PDUFA Dec 15, 2025; investments: Armata $15M, Lyndra $10.2M, Beacon Biosignals $17.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":296715000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133824,"accession_number":"0001104659-25-074730","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.","GSK royalty revenue $67.3M, flat YoY; IST U.S. net product sales $29.0M (+54% YoY).","ZEVTERA (ceftobiprole) commercially launched in U.S. July 2025 for three indications.","Zoliflodacin NDA accepted with Priority Review; PDUFA target date Dec 15, 2025; no AdCom planned.","Cash & equivalents $397.5M; strategic healthcare asset portfolio valued at $449.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":188915000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150559,"accession_number":"0001104659-25-051614","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Innoviva stockholders elect five directors and approve advisory compensation vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Derek Small, Mark DiPaolo, Jules Haimovitz, Sarah Schlesinger, Pavel Raifeld.","Non-binding advisory vote on executive compensation approved: 45.8M for, 2.1M against, 6.1M broker non-votes.","Ratification of Deloitte & Touche as auditor for 2025: 54.0M for, 118k against, 4.6k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150558,"accession_number":"0001104659-25-045556","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q1 net loss $46.6M on $78.8M investment write-down; IST sales up 52%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.6M ($0.74/share) vs net income of $36.5M in Q1 2024 due to $78.8M unfavorable fair value changes on equity investments.","Royalty revenue from GSK was $61.3M, largely flat year-over-year.","U.S. net product sales from IST (GIAPREZA, XACDURO, XERAVA) grew 52% to $26.4M; total net product sales $30.3M.","Income from operations rose 61% to $41.4M; cash and equivalents $319.1M at quarter end.","Zoliflodacin NDA on track for H1 2025 filing; ZEVTERA U.S. launch expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":88632000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169524,"accession_number":"0001104659-25-017461","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q4 GSK royalties $66M, IST sales up 47% YoY; ZEVTERA launch mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GSK royalties $66.0M; full year $255.6M vs $252.7M in 2023.","U.S. net product sales $24.9M in Q4, full year $80.9M (+47% YoY).","Acquired U.S. rights to ZEVTERA; launch expected mid-2025.","Zoliflodacin NDA submission to FDA on track for early 2025.","Cash and receivables $391.4M; net income $20.3M in Q4 ($0.32 EPS)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":358711000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186572,"accession_number":"0001104659-24-114800","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q3 2024 royalty revenue $60.5M (+6% YoY); net product sales $27.8M; net income $1.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalty revenue from GSK $60.5M, up 6% YoY; core royalty platform continued strong performance.","US net product sales $19.7M (+68% YoY) driven by GIAPREZA $13.1M, XACDURO $4.3M, XERAVA $2.3M.","Net income $1.2M ($0.02 basic EPS) vs $82.0M ($1.26) in Q3 2023; unfavorable $35.2M fair value change on Armata investment.","XACDURO nominated for Prix Galien USA Award; zoliflodacin NDA submission expected early 2025.","Cash and cash equivalents $260.6M; royalty and product sales receivables $91.1M as of Sep 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":266905000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203148,"accession_number":"0001104659-24-084357","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q2 2024: net loss $34.7M on investment fair-value hit; royalty revenue $67.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GSK royalty revenue $67.2M vs $65.7M YoY; net product sales $21.7M (+38% YoY).","Net loss of $34.7M ($0.55 basic loss) due to $90.7M unfavorable change in equity investments.","License revenue $14.5M including $8M milestone from XACDURO approval in China.","Completed $100M share repurchase program; repurchased 0.4M shares in Q2 for $5.3M.","XACDURO approved in China; named preferred agent in 2024 IDSA guidance; XERAVA recommended by SIS guidelines."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":177397000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219453,"accession_number":"0001104659-24-073416","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Innoviva 2024 annual meeting: all six director nominees elected; say-on-pay and auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with votes for ranging from 48.3M (Srivastava) to 53.7M (Small).","Non-binding advisory vote on executive compensation approved: 52.8M for, 1.1M against.","Ratification of Deloitte & Touche as auditor for FY2024 passed: 56.3M for, 0.27M against.","Broker non-votes were 2.5M shares for director elections and say-on-pay; none for auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219452,"accession_number":"0001104659-24-060280","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Innoviva posts revised investor presentation; content not fully available for analysis","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Revised investor presentation made available on company website and as Exhibit 99.1 to 8-K on May 13, 2024.","Presentation text truncated in filing excerpt; no specific changes or financial data extracted.","No guidance revisions, earnings results, or material events identifiable from available text.","Confidence limited due to incomplete exhibit; recommend reviewing full presentation on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219451,"accession_number":"0001104659-24-058747","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q1 net income $36.5M ($0.58 basic EPS); product sales up 66% YoY to $19.1M; GSK royalties $61.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $36.5M ($0.58 basic EPS) vs $34.9M ($0.51) in Q1 2023.","Net product sales $19.1M, +66% YoY, driven by XACDURO launch and GIAPREZA growth.","GSK royalty revenue $61.9M, up from $60.3M in Q1 2023.","Repurchased 0.6M shares for $9.7M in Q1 2024; completed $5.3M buyback post-quarter.","Positive Phase 3 zoliflodacin results for uncomplicated gonorrhea; NDA submission expected early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":77499000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219450,"accession_number":"0001193125-24-123033","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Innoviva appoints Derek Small to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Derek Small appointed effective April 29, 2024; independent director.","Managing Director at Luson Bioventures; former CEO of Assembly Biosciences and Naurex.","Receives initial RSU award of $125,000, prorated RSU of $18,750, and options for 833 shares.","Annual cash retainer of $50,000; standard indemnification agreement with Innoviva."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239286,"accession_number":"0001104659-24-029378","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q4 net income $61.5M, royalty revenue $69.6M; product sales up 35% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $61.5M ($0.97 EPS) vs $68.3M loss in Q4 2022; full-year net income $179.7M.","Q4 GSK royalty revenue $69.6M; net product sales $19.7M (+35% YoY) driven by GIAPREZA ($13.1M) and XERAVA ($5.2M).","Repurchased 1.1M shares for $15.4M in Q4; full-year repurchases $76.5M; $15M authorization remaining.","XACDURO approved for HABP/VABP; zoliflodacin met Phase 3 primary endpoint; NDA filing within 12 months.","Cash and receivables >$275M; strategic assets valued at $561M; invested $5M in Gate Neurosciences."],"consensus_eps_estimate":null,"consensus_eps_actual":2.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":310463000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256789,"accession_number":"0001104659-23-114509","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Innoviva's zoliflodacin meets primary endpoint in Phase 3 gonorrhea trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zoliflodacin met primary efficacy endpoint with non-inferiority to ceftriaxone+azithromycin in urogenital gonorrhea (point estimate 5.3% difference, 95% CI 1.4%-8.7%).","Microbiological cure rates >90% in both arms; 90.9% for zoliflodacin vs 96.8% for comparator in Micro-ITT population.","Secondary analyses at rectal and pharyngeal sites showed comparable cure rates but were not powered for statistical significance.","Safety profile favorable: no serious AEs, discontinuations, or deaths; headache (9.9%) most common TEAE for zoliflodacin.","Global Phase 3 trial enrolled 927 patients across 16 sites in US, South Africa, Belgium, Netherlands, and Thailand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256788,"accession_number":"0001104659-23-113410","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q3 2023: GSK royalties $57M, net income $82M, launches XACDURO, positive Phase 3 zoliflodacin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GSK royalty revenue $57.0M (Q3 2023) vs $65.6M (Q3 2022); net product sales $13.7M.","Net income $82.0M ($1.26 basic EPS) vs $265.5M ($3.81) in Q3 2022; prior year included gain on sale.","Launched XACDURO for Acinetobacter HABP/VABP; announced positive Phase 3 zoliflodacin for gonorrhea.","Appointed Stephen Basso as CFO; repurchased $11.0M of stock in Q3.","Cash $180.0M; invested $25M in Armata Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":224623000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274152,"accession_number":"0001104659-23-095406","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Innoviva appoints Stephen Basso as CFO with $450K salary, $100K signing bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Basso appointed CFO effective August 21, 2023; brings 30+ years pharma/finance leadership experience.","Base salary $450K, target annual bonus 40% of base, one-time $100K signing bonus (repayable if leaves within 1 year for cause).","Initial grant of 150,000 nonqualified stock options; vesting 25% on 1st anniversary, then quarterly over 3 years.","Severance: 12 months salary continuation, COBRA, and accelerated vesting on change-in-control termination without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274151,"accession_number":"0001104659-23-088390","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Innoviva receives Nasdaq notice for audit committee non-compliance after director resignation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Innoviva on Aug 2, 2023, that Audit Committee has only 2 independent directors after Dr. Deborah L. Birx resigned July 10.","Company has cure period until the earlier of next annual meeting or July 10, 2024 to regain compliance with Nasdaq Rule 5605.","No immediate impact on Nasdaq listing or common stock trading.","Board is evaluating committee composition and intends to comply fully before cure period ends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274150,"accession_number":"0001104659-23-086806","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q2 2023: GSK royalties $65.7M, XACDURO FDA approved, net income $1.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GSK royalties of $65.7M (RELVAR/BREO $54.4M, ANORO $11.3M) vs $111.7M in Q2 2022 due to TRELEGY royalty sale.","Net product sales $15.7M (GIAPREZA $11.2M, XERAVA $4.5M); $3.0M license milestone from XACDURO FDA approval.","Net income $1.3M ($0.02 basic EPS) vs $0.9M ($0.01) in Q2 2022; cash + receivables $254M.","Repurchased 775,504 shares for $9.2M in Q2 2023; invested $25M in Armata (NYSE: ARMP) on July 11, 2023.","On May 23, 2023, FDA approved XACDURO for HABP/VABP caused by Acinetobacter; launch expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":157364000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274149,"accession_number":"0001104659-23-079823","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Director Deborah Birx resigns from Innoviva board to become CEO of majority-owned Armata Pharmaceuticals","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah L. Birx resigned from the Board and Audit Committee effective July 10, 2023.","She accepted the CEO position at Armata Pharmaceuticals, a majority-owned Innoviva subsidiary.","Resignation was not due to any disagreement with the Company's operations, policies, or controls.","No other Board changes or disagreements disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291344,"accession_number":"0001104659-23-064192","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Innoviva posts revised investor presentation; no material new facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted updated corporate presentation on its website on May 24, 2023.","No updated financial guidance, M&A, or operational changes included in the filing.","Presentation content not summarized; investors should review directly for any changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291343,"accession_number":"0001104659-23-063704","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Innoviva board elected; Sapna Srivastava receives 21.9M against votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; Dr. Sapna Srivastava received ~32.6M for, ~21.9M against.","Advisory vote on executive compensation approved with ~51.96M for, ~2.51M against.","Stockholders approved one-year frequency for non-binding advisory compensation votes.","Ratification of Deloitte & Touche as auditor approved with ~58.8M for, 11,607 against.","Approval of Innoviva 2023 Employee Stock Purchase Plan with ~54.3M for, ~130,716 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291342,"accession_number":"0001104659-23-057825","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q1 net income $34.9M ($0.51 EPS); GSK royalties $60.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $34.9M ($0.51 basic EPS) vs $15.8M ($0.23) YoY.","GSK royalty revenue $60.3M, down from $93.5M YoY due to TRELEGY royalty sale in July 2022.","Net product sales & license revenue $19.5M ($9M GIAPREZA, $2.5M XERAVA, $8M milestone from China XERAVA approval).","Repurchased $40.3M of common stock (3.4M shares); paid off $96.2M of 2023 convertible notes.","FDA advisory committee unanimously voted 12-0 for sulbactam-durlobactam; PDUFA target date May 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":76372000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291341,"accession_number":"0001193125-23-128122","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Innoviva Chairman George Bickerstaff to retire at 2023 Annual Meeting; board to shrink to 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Bickerstaff, III, Chairman since 2020, will not stand for reelection; departure is not due to any disagreement.","Board size to be reduced from seven to six members immediately after the 2023 Annual Meeting.","New Chairperson will be elected by the Board following the meeting; no successor named yet.","Bickerstaff cited focus on other professional and philanthropic pursuits, including role at International Vaccine Institute."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312134,"accession_number":"0001104659-23-026810","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva reports Q4 2022 royalties of $54.7M, pre-tax loss of $64.7M on $85.4M fair-value decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross royalty revenues of $54.7M from GSK for RELVAR/BREO and ANORO ELLIPTA in Q4 2022.","Income before taxes was a loss of $64.7M vs. income of $56.5M in Q4 2021, driven by $85.4M decline in fair value of investments.","Net product sales of $14.6M from GIAPREZA and XERAVA in Q4 2022.","Board authorized $100M share repurchase program; $30M convertible debt facility with Armata closed in January 2023.","FDA granted priority review for SUL-DUR NDA; PDUFA date May 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":2.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":331339000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312133,"accession_number":"0001104659-23-000897","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Innoviva appoints Dr. Sapna Srivastava to board, effective Jan 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sapna Srivastava appointed to Board as independent director, effective Jan 1, 2023.","Srivastava brings experience as former CFO of Intellia Therapeutics and Abide Therapeutics, and 15 years as biotech analyst.","Received initial RSU award of $125,000, prorated RSU of $56,250, and option for 2,500 shares.","Annual cash retainer of $50,000 for board service.","Bylaws amended to remove reference to SmithKline Beecham and update director nomination procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330707,"accession_number":"0001104659-22-116491","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q3 gross royalties $65.6M, income before taxes surges to $286.4M on TRC sale gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross royalty revenues of $65.6M (flat YoY) from RELVAR/BREO ($55.7M) and ANORO ($9.9M).","Income before taxes rose to $286.4M from $123.2M, primarily due to gain from sale of 15% TRC interest to Royalty Pharma for $282M.","Completed acquisitions: Entasis for $42.4M and La Jolla for net cash $150.5M, expanding hospital/infectious disease portfolio.","Board authorized new $100M share repurchase program; no termination date, management discretion.","GSK reported RELVAR/BREO net sales $371.1M (+3% YoY) and ANORO $153.0M (-15% YoY), reflecting currency and pricing headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":265536000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330706,"accession_number":"0001104659-22-112462","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K/A","filed_at":"2022-10-28T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Innoviva completes sale of 15% stake in Theravance Respiratory to Royalty Pharma for $281.9M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold 750 Class A and 750 Class C Units (15% ownership) of TRC to Royalty Pharma Investments for $281.9M upfront.","Upfront cash: $277.5M for equity plus $4.4M distribution of TRC cash.","Eligible for $50M contingent sales-based milestone payment from buyer.","Sale closed July 20, 2022; pro forma financials reflect disposition as if effective Jan 1, 2021.","Pro forma condensed consolidated statements for six months ended June 30, 2022 and FY 2021 filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348224,"accession_number":"0000899140-22-000705","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-09-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Innoviva posts updated investor presentation; no specific details available in filing text.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing indicates a revised investor presentation was posted on the company website on September 14, 2022.","Presentation attached as Exhibit 99.1 but its content is not provided in the filing excerpt.","Investors should refer directly to the presentation on Innoviva's website for any material updates.","No financial data, guidance, or strategic changes can be inferred from this procedural 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348223,"accession_number":"0001104659-22-093694","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Innoviva files risk factor update with no specific new disclosure","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an 8-K to supplement risk factors from its June 30, 2022 10-Q and 2021 10-K.","Updated risk factors cover clinical trial failure, patient enrollment delays, and third-party dependence.","No specific new events, financial results, or business developments were reported.","The risk factor language is standard biotech boilerplate with no material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348222,"accession_number":"0001193125-22-226123","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-08-22T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Innoviva completes acquisition of La Jolla Pharmaceutical for $6.23 per share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer accepted 21,703,224 shares (~87.03% of outstanding) at $6.23 per share, no interest.","Merger completed on August 22, 2022, with La Jolla surviving as wholly-owned subsidiary.","All outstanding shares (other than Innoviva-Owned and La Jolla-Owned) converted to $6.23 cash per share.","Series C-1 Preferred Shares converted to cash equal to 1,724.04 times the Merger Consideration.","Options with exercise price below $6.23 received cash for spread; options at or above $6.23 cancelled for no consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348221,"accession_number":"0001104659-22-083169","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q2 royalties up 7% to $111.7M; acquires Entasis, agrees to buy La Jolla","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalties increased 7% to $111.7M in Q2 2022 vs Q2 2021.","Income from operations decreased 14% to $82.6M due to Entasis consolidation.","Completed acquisition of remaining ~40% of Entasis for $2.20/share ($42M total).","Entered merger to acquire La Jolla Pharmaceutical for $6.23/share (~$149M enterprise value).","Sold 15% stake in Theravance Respiratory Co. to Royalty Pharma for ~$282M upfront plus potential $50M milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":198279000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348220,"accession_number":"0001140361-22-026440","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-07-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Innoviva closes sale of 750 Class A and 750 Class C units of Theravance Respiratory to Royalty Pharma","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of 750 Class A and 750 Class C units of Theravance Respiratory Company, LLC to Royalty Pharma Investments 2019 ICAV.","Closing date was July 20, 2022, as previously announced on July 13, 2022.","The seller was Innoviva, Inc. and its wholly-owned subsidiary Innoviva TRC Holdings LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348219,"accession_number":"0001140361-22-025945","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-07-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Innoviva sells 15% TRC stake to Royalty Pharma for ~$282M upfront plus $50M milestone","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $282M; potential $50M sales-based milestone payment.","Retained full ownership of TRC's investments in InCarda, ImaginAb, Gate Neurosciences, and Nanolive SA.","Retained royalty rights on ANORO ELLIPTA and RELVAR/BREO ELLIPTA after closing.","Theravance Biopharma concurrently selling its 85% TRC stake to Royalty Pharma.","Transaction expected to close July 2022; includes amendments to GSK collaboration agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348218,"accession_number":"0001140361-22-025724","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Innoviva completes acquisition of Entasis Therapeutics for $2.20/share, total ~$42.4M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed on July 11, 2022; Entasis becomes wholly-owned subsidiary of Innoviva.","Total consideration of approximately $42.4M paid for all outstanding shares tendered at $2.20 per share.","Entasis' pipeline includes SUL-DUR for Gram-negative bacteria; NDA submission planned for Q3 2022.","Entasis common stock to be delisted from Nasdaq Global Market following acquisition.","Innoviva funded the purchase from its own resources; deal creates new growth channel and diversifies revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348217,"accession_number":"0001140361-22-025657","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Innoviva to acquire La Jolla Pharmaceutical for $6.23/share in cash, ~$149M EV","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Offer price $6.23/share ($5.95 base + $0.28 from non-core asset sale); 70% premium to 30-day VWAP.","Implied enterprise value approximately $149 million; tender offer expected within ~30 business days.","Adds GIAPREZA (angiotensin II) and XERAVA (eravacycline) to Innoviva's infectious disease portfolio.","Stockholders holding ~40% of La Jolla shares signed support agreement to tender shares.","Transaction unanimously approved by both boards; subject to majority tender and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364909,"accession_number":"0001140361-22-020321","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Innoviva to acquire Entasis Therapeutics for $2.20/share cash tender offer","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Offer price of $2.20 per share; all-cash transaction valued at implied equity value of ~$80M (based on 36.4M shares outstanding).","Merger agreement unanimously approved by boards of Innoviva, Merger Sub, and Entasis.","Support agreements with TPG GP A, LLC and independent directors covering ~2.32% of shares; they will tender in the offer.","Tender condition requires at least one more than 50% of shares not owned by Innoviva or Entasis CEO; no financing contingency disclosed.","Entasis options and RSUs will be converted into cash or Innoviva stock; warrants replaced with Innoviva warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364903,"accession_number":"0000899140-22-000500","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K/A","filed_at":"2022-05-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Innoviva amends 8-K to correct vesting date for CEO options grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amends prior 8-K to fix typo in vesting date for options granted to CEO Pavel Raifeld on May 2, 2022.","First 25% of options will vest on May 20, 2023; no change to other vesting terms.","No other modifications made to the original filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364908,"accession_number":"0000899140-22-000493","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Innoviva enters new CEO employment agreement with Pavel Raifeld through April 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary $455k in year one, $500k in year two; bonus target 70% then 80% of salary.","Option grant of 150,000 shares; 25% vesting immediately, rest quarterly over three years with acceleration on change-in-control involuntary termination.","Severance without cause: continued salary for longer of 6 months or through April 30, 2024, plus pro-rata bonus subject to release.","Initial term May 1, 2022 to April 30, 2024; automatic renewal for one-year periods unless 60-day non-extension notice given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364907,"accession_number":"0000899140-22-000487","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Innoviva elects six directors at annual meeting; say-on-pay passes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected 6 directors at Apr 25, 2022 meeting; each term expires at 2023 annual meeting.","Dr. Sarah Schlesinger received 36.6M votes for, 16.7M against/abstain — highest opposition among nominees.","Say-on-pay advisory vote approved: 51.5M for, 1.7M against, 0.1M abstain, 5.1M broker non-votes.","Ratification of Deloitte & Touche as auditor for FY2022: 58.0M for, 0.3M against, 23k abstain.","Broker non-votes of ~5.1M shares on director elections and say-on-pay proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364906,"accession_number":"0001104659-22-051406","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q1 royalties up 5% to $93.5M; invested $45M in Armata, $15M in Entasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross royalty revenues of $93.5M (+5% YoY); TRELEGY sales up 33% to $450.9M.","Issued $261M 2.125% convertible notes due 2028; repurchased $144.8M of 2023 notes.","Invested $45M in Armata for ~69% ownership; $15M convertible debt financing to Entasis.","Non-binding offer to acquire Entasis at $2.00/share; consolidated Entasis financials.","Net cash $183.3M (excl. $33.5M Entasis cash); receivables $93.5M from GSK."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":90059000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364905,"accession_number":"0000899140-22-000449","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Innoviva posts revised investor presentation on April 7, 2022","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation available on company website; no specific financial or operational updates disclosed in the filing.","Filing also references Definitive Proxy Statement filed March 25, 2022 for 2022 annual meeting.","Content of revised presentation not included in exhibit, limiting ability to assess material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364904,"accession_number":"0000899140-22-000438","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Innoviva subsidiary contributes $110M to ISP Fund LP, fulfilling prior commitment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Innoviva Strategic Partners contributed $110,000,000 to ISP Fund LP on March 30, 2022.","Contribution fulfills a commitment from May 2021 related to a distribution from the Partnership.","Audit committee of Innoviva's Board approved the contribution.","No new financial or operational impact beyond routine capital movement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384508,"accession_number":"0001104659-22-038081","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-03-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Innoviva dismisses Grant Thornton, hires Deloitte as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Grant Thornton effective March 25, 2022; Deloitte appointed for FY 2022.","No adverse opinions or qualifications in Grant Thornton's reports for 2020 and 2021.","No disagreements with Grant Thornton on accounting principles or audit scope during those periods.","No consultations with Deloitte on matters under Reg S-K Item 304 prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384507,"accession_number":"0001104659-22-036192","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["1.01","2.03","3.02"],"status":"ready","headline":"Innoviva closes additional $36M of 2.125% convertible notes due 2028; total notes now $261M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $36M aggregate principal additional convertible notes; net proceeds ~$34.5M after discounts and expenses.","Notes mature 2028, same terms as $225M initial notes; capped call transactions entered to limit dilution.","Capped call cap price initially $33.9850/share (~75% premium to March 2 closing price).","Up to 1,853,759 shares issuable upon conversion of additional notes; total across all notes up to 13,439,751 shares.","Proceeds used $2.9M for capped call costs; remainder for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384506,"accession_number":"0001104659-22-031613","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Innoviva closes $225M 2.125% convertible senior notes due 2028; repurchases $144.8M of 2023 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $225M principal of 2.125% convertible notes due March 15, 2028; initial conversion price $26.22 (35% premium to $19.42 close on March 2, 2022).","Net proceeds ~$216.8M; used $18.1M for capped calls and $165.6M to repurchase $144.8M of 2.125% convertible subordinated notes due 2023.","Capped call transactions entered with option counterparties; cap price initially $33.9850 (75% premium over March 2 closing price).","Initial purchasers granted option to buy up to an additional $45M of notes within 13 days.","Notes redeemable at Innoviva's option on or after March 20, 2025 if stock exceeds 130% of conversion price for a specified period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384505,"accession_number":"0001104659-22-017148","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Innoviva Q4 2021 royalties up 18% to $111.1M; announces $45M strategic investment in Armata","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross royalty revenues $111.1M in Q4 2021 (+18% YoY); full year 2021 $405.7M (+19%).","Income from operations $104.5M (+23% YoY); diluted EPS $2.87 (+40%).","Invested $4M in Armata in Q4 2021 and additional $45M in Feb 2022, expected to own ~70%.","TRELEGY global net sales up 53% to $480.2M; ANORO down 17%; RELVAR/BREO up 3%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":391866000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402359,"accession_number":"0001104659-21-149134","cik":1080014,"company_name":"Innoviva, Inc.","ticker":"INVA","form_type":"8-K","filed_at":"2021-12-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Innoviva posts investor presentation; no material new financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made investor presentation available on website on December 13, 2021.","Presentation contains only forward-looking statements and no specific financial updates.","Exhibit text is truncated; no quantifiable information on revenue, earnings, or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1633387577.9792771,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-13T23:59:59+00:00|402359"}